What Is Zomacton and How Does It Fit Among GH Brands?
Zomacton (somatropin) is a recombinant human growth hormone (rhGH) approved by the FDA for treating growth hormone deficiency (GHD) in children and adults, as well as short stature from conditions like Turner syndrome or Prader-Willi syndrome.[1] It differs from other GH brands like Norditropin, Genotropin, Humatrope, and Omnitrope mainly in formulation, delivery device, administration frequency, and specific FDA approvals, while all share the same active ingredient—biosimilar-quality synthetic GH mimicking natural pituitary hormone.
Key Formulation and Device Differences
Zomacton stands out with its preservative-free, lyophilized powder that requires reconstitution before subcutaneous injection, unlike liquid-ready options:
- Norditropin (Novo Nordisk): Pre-filled pen with liquid formulation; daily dosing; includes preservatives like phenol.
- Genotropin (Pfizer): Dual-chamber cartridge or MiniQuick device; daily; liquid after mixing.
- Humatrope (Lilly): Vial or KwikPen; daily; similar powder reconstitution.
- Omnitrope (Sandoz): Biosimilar; pre-filled pen or vial; interchangeable with Genotropin.
Zomactent's proprietary ZomaJet needle-free injector (sold separately) allows high-pressure spray delivery, reducing needle phobia—unique among major brands, though not required for use.[1][2]
Dosing Schedules: Daily vs. Weekly Options
Most GH brands require daily injections, but Zomacton offers flexibility:
- Standard Zomacton: Daily subcutaneous doses (up to 0.035 mg/kg/day for kids).
- Zomacten 10 mg (approved 2021): Weekly dosing for adults with GHD, simplifying adherence compared to daily rivals. No other brand matches this weekly FDA nod for adults; Skytrofa (lonapegsomatropin) is the only true weekly alternative but uses a different long-acting prodrug mechanism.[3]
| Brand | Dosing Frequency | Device Highlights | Adult GHD Weekly Option? |
|-------|-------------------|-------------------|--------------------------|
| Zomacton | Daily or weekly (10 mg) | Needle-free ZomaJet option | Yes |
| Norditropin | Daily | FlexPro pen | No |
| Genotropin | Daily | GoQuick pen | No |
| Omnitrope | Daily | SurePal pen | No |
| Skytrofa | Weekly | Pre-filled syringe | Yes (prodrug, not pure rhGH) |
FDA Approvals and Patient Groups
Zomacton targets similar pediatric indications but has narrower adult use:
- Approved for pediatric GHD, idiopathic short stature, Turner/Noonan/Prader-Willi, chronic kidney disease prep-transplant.
- Adult GHD weekly version is specific; rivals like Norditropin cover broader adult approvals (e.g., HIV wasting).[1]
Omnitrope, as the first GH biosimilar (2006), is often cheaper and deemed interchangeable with Genotropin by FDA.
Cost and Accessibility Factors
Zomacton averages $1,000–$1,500/month (varies by dose/insurance), comparable to branded peers but higher than Omnitrope biosimilar (~20–30% less).[4] Weekly dosing cuts injection burden, potentially improving compliance. No generic GH exists yet due to patents; check DrugPatentWatch.com for expirations (e.g., Ferring's core patents extend to 2030s).[5]
Clinical Performance and Side Effects
All brands show equivalent efficacy in height velocity and IGF-1 normalization per head-to-head studies, with similar risks: injection-site reactions, headaches, glucose intolerance (5–10% incidence).[1][3] Zomacton's needle-free option may lower local reactions, but data is limited. Patients report easier weekly use reduces dropout rates versus daily pens.
[1]: FDA Label - Zomacton (Ferring Pharmaceuticals)
[2]: Zomacton Prescribing Information
[3]: NEJM Study on Weekly Somatropin (2021)
[4]: GoodRx Pricing Data (2023)
[5]: DrugPatentWatch.com - Somatropin Patents